WikiMD is the world's largest medical encyclopedia with
29,039 pages, 4,107,628 edits & 35,806,679 views.
Sunitinib
Information about Sunitinib
Sunitinib is multi-specific tyrosine kinase receptor inhibitor that is used in the therapy of gastrointestinal stromal tumors and advanced renal cell carcinoma.
Liver safety of Sunitinib
Sunitinib therapy is associated with transient elevations in serum aminotransferase and bilirubin levels and rare instances of clinically apparent acute liver injury.
Mechanism of action of Sunitinib
Sunitinib (soo ni' ti nib) is an inhibitor of several tyrosine kinase receptors which are associated with tumor growth and angiogenesis. The tyrosine kinase receptors of cancer cells are often mutated and can cause unregulated cell growth and proliferation. Sunitinib is one of several tyrosine kinase receptor inhibitors that have been introduced into cancer chemotherapy and are specially directed at molecular abnormalities that occur in cancer cells. Inhibition of the receptor can lead to dramatic reversal of progression the cancer, although sometimes limited by the development of tumor resistance caused by mutations in the kinase. Sunitinib has special activity against the abnormal tyrosine kinase (cKit) that is found in gastrointestinal stromal tumors (GIST). Sunitinib also has activity against the receptors for platelet derived growth factor (PDGF) and vascular endothelial growth factor (VEGF).
FDA approval information for Sunitinib
Sunitinib received approval for use in the United States in 2006. Current indications are for unresectable or metastatic GIST with positive cKit (CD117), advanced renal cell carcinoma and advanced pancreatic neuroendocrine tumors. Sunitinib is also used in patients who are intolerant or become resistant to imatinib, the initial tyrosine kinase receptor inhibitor that has special activity against chronic myelogenous leukemia (CML) bearing the Philadelphia chromosome.
Dosage and administration for Sunitinib
Sunitinib is available in capsules of 12.5, 25 and 50 mg under the brand name Sutent. The typical dose of sunitinib is in cycles of 4 weeks, followed by a rest period of 2 weeks, using a starting dose of 37.5 or 50 mg daily and increasing or decreasing in 12.5 mg increments, with each cycle based upon tolerance and response.
Side effects of Sunitinib
Side effects include fatigue, diarrhea, anorexia, skin discoloration, rash, hand-foot syndrome, edema, muscle cramps, arthralgias, headache, abdominal discomfort, anemia, cough, and pruritus. Uncommon side effects include heart failure, pancreatitis and renal failure.
Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ
Cost and Coupons - Sunitinib
- GoodRx compare cost & coupons for Sunitinib
- Find the lowest cost of Sunitinib
- Search for Coupons for Sunitinib
Reviews for Sunitinib
Learn more about Sunitinib
- Dailymed label info
- Scientific articles
- Drug portal Sunitinib
- toxicity info on Sunitinib
- FDA Sunitinib
Latest research (Pubmed)
External links
WikiMD needs you!
This WikiMD article Sunitinib is a stub.
If you are a healthcare professional familiar with the topic Sunitinib, or
A subject matter expert or authority on Sunitinib, you can help us.
About | Mission | Paid editors welcome!
| Sunitinib is part of WikiMD's Physician reviewed^ articles available 4free, 4all, 4ever! |
|---|
| Medicine: Health - Encyclopedia - Topics - Diseases - Cancer - Rare diseases - Random Page Navigation: Drugs - Wellness - Obesity - Diet - Ketogenic diet - W8MD weight loss diet - Editors: Recently Edited Pages - Alphabetical Order - Sponsors - USMLE The content on or accessible through WikiMD is for informational purposes only. WikiMD is not a substitute for professional medical advice. ^See full Disclaimers |
 Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP* |
